| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 16,044 | 15,383 | ||
| General and administrative | 7,761 | 6,523 | ||
| Total operating expenses | 23,805 | 21,906 | ||
| Loss from operations | -23,805 | -21,906 | ||
| Interest income | 3,456 | 3,667 | ||
| Other income | 71 | 171 | ||
| Total other income | 3,527 | 3,838 | ||
| Net loss | -20,278 | -18,068 | ||
| Unrealized gain on marketable securities | 237 | -118 | ||
| Total other comprehensive gain | 237 | -118 | ||
| Comprehensive loss | -20,041 | -18,186 | ||
| Net loss per share, basic (in dollars per share) | -0.46 | -410 | ||
| Net loss per share, diluted (in dollars per share) | -0.46 | -410 | ||
| Weighted-average number of common shares outstanding, basic (in shares) | 44,255,053 | 44,116,997 | ||
| Weighted-average number of common shares outstanding, diluted (in shares) | 44,255,053 | 44,116,997 | ||
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)